This report introduces Samsung Medison’s ultrasound-based quantification technologies—EzHRI™, TAI™, and TSI™—designed to support non-invasive diagnosis and monitoring of fatty liver (NAFLD).
Fatty liver disease affects approximately 25–30% of adults worldwide, often progressing from fat deposits to steatohepatitis, fibrosis, or cirrhosis. Early diagnosis and consistent monitoring are essential.
EzHRI™ (Hepatorenal Index) uses deep learning to automatically segment liver and kidney areas, recommend ROI placement, and calculate brightness ratios, offering a more efficient and reproducible HRI measurement workflow.
TAI™ (Tissue Attenuation Imaging) quantifies signal attenuation, which increases in more severe fatty liver cases. By analyzing changes in ultrasound signal frequencies with depth, TAI™ provides an objective attenuation index for NAFLD staging.
TSI™ (Tissue Scatter Distribution Imaging) measures the backscatter distribution of ultrasound signals and models it statistically to indicate changes in tissue characteristics. The TSI™ value reflects the scattering pattern shifts caused by fat accumulation.
The report details how these tools provide measurements for echogenicity, attenuation, and backscatter, allowing for quantified liver fat assessment rather than relying solely on visual interpretation. With clear workflows, guided ROI positioning, and reliability indicators (e.g., R² values), the tools streamline the diagnostic process.
In conclusion, EzHRI™, TAI™, and TSI™ offer non-invasive, quantitative, and user-friendly tools that help clinicians diagnose and monitor fatty liver more accurately and efficiently using ultrasound.
For a broader overview of Samsung’s liver solutions, please refer to the Liver Solution Leaflet.
